Insilico Medicine appoints Dr. Feng Ren as co-CEO
Dr. Feng Ren, Chief Scientific Officer (CSO) and head of global research and development is named co-CEO of Insilico Medicine Highlights: Insilico Medicine is a global, end-to-end, fully-integrated AI-powered biotechnology company with three business models: AI platform, collaboration, and internal pipeline. It utilizes AI and a fully distributed, highly parallel discovery model to rapidly develop its own drugs. Since 2021, the company has nominated 8 preclinical candidates and reached Phase I c...
Feng Ren United States Alex Zhavoronkov Harvard University Head Of Global Research Chief Scientific Officer
Source: singaporestar.com